Single-Family Offices or Venture Capitalists? Entrepreneurs’ Perceptions of Investor Attractiveness at the Deal-Origination Stage
Family Business Review · 10.11.2026
DOI: 10.1177/08944865261501674 ↗Kurz gefasst
Fachartikel in der Zeitschrift Family Business Review, online erschienen am 10.11.2026. Verfasst von Isabelle Amann und 2 weiteren Autor:innen. Die Arbeit nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Deciding whom to initially contact for potential venture funding is an important entrepreneurial choice, particularly at the deal-origination stage when limited information makes signals about investor characteristics essential. Grounded in signaling theory, this study builds on an experiment exploring entrepreneurs’ perceived attractiveness of single-family offices (SFOs) compared to venture capitalists (VCs). The findings reveal that SFOs are perceived as more attractive to initial contacts than VCs, identifying humanization and a feeling of closeness as underlying psychological mechanisms. The study contributes to a nuanced understanding of the psychological mechanisms driving entrepreneurs’ perceptions of the family signal, bridging family business and psychology research.
Zitieren
APA
Amann, I., Lude, M., & Prügl, R. (2026). Single-Family Offices or Venture Capitalists? Entrepreneurs’ Perceptions of Investor Attractiveness at the Deal-Origination Stage. Family Business Review. https://doi.org/10.1177/08944865261501674
Vancouver
Amann I, Lude M, Prügl R. Single-Family Offices or Venture Capitalists? Entrepreneurs’ Perceptions of Investor Attractiveness at the Deal-Origination Stage. Family Business Review. 2026. doi:10.1177/08944865261501674
BibTeX
@article{Amann2026,
author = {Amann, Isabelle and Lude, Maximilian and Prügl, Reinhard},
title = {Single-Family Offices or Venture Capitalists? Entrepreneurs’ Perceptions of Investor Attractiveness at the Deal-Origination Stage},
journal = {Family Business Review},
year = {2026},
doi = {10.1177/08944865261501674}
}
EUVIMED